BBI - Brickell Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9319
-0.0161 (-1.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.9480
Open0.9480
Bid0.0000 x 2200
Ask0.0000 x 4000
Day's Range0.9115 - 0.9480
52 Week Range0.8800 - 6.5100
Volume657,216
Avg. Volume1,471,606
Market Cap9.016M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.1670
Earnings DateMay 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $1.15, for total gross proceeds of approximately $20.1 million, before underwriting discounts and commissions and offering expenses payable by Brickell.

  • GlobeNewswire

    Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the release of positive Phase 3 pivotal study results from its development partner, Kaken Pharmaceutical Co. Ltd., in Japan. All primary and secondary efficacy endpoints of the study were met.

  • Brickell Biotech (NASDAQ:BBI) Is Arguably In A Tricky Situation
    Simply Wall St.

    Brickell Biotech (NASDAQ:BBI) Is Arguably In A Tricky Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • GlobeNewswire

    Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. “Brickell has continued to make progress during the first quarter of 2020, and we remain committed to advancing sofpironium bromide into Phase 3 clinical studies in the U.S.,” commented Robert Brown, Chief Executive Officer of Brickell. Today, Brickell announced that, based on a preliminary review of the top-line results from the 12-month Phase 3 open-label long-term safety study, in 300 subjects >9 years old with primary axillary hyperhidrosis, sofpironium bromide gel, 5% and 15% was safe and generally well tolerated, which was consistent with the earlier Phase 2 clinical trial results.

  • GlobeNewswire

    Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, May 13, 2020. Brickell’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases.

  • GlobeNewswire

    Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., March 18, 2020 -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated.

  • ACCESSWIRE

    Brickell Biotech Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Brickell Biotech Inc (NASDAQ:BBI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 at 4:30 ...

  • GlobeNewswire

    Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Wednesday, March 18, 2020. Brickell’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at http://www.brickellbio.com/.

  • GlobeNewswire

    Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive results from its development partner, Kaken Pharmaceutical Co. Ltd.’s Phase 3 pivotal study in Japan were selected for oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.

  • Here’s Why E*Trade (ETFC), Adesto (IOTS) and Brickell Biotech (BBI) Shares Skyrocketed Today
    TipRanks

    Here’s Why E*Trade (ETFC), Adesto (IOTS) and Brickell Biotech (BBI) Shares Skyrocketed Today

    Keeping a finger on the pulse of developments in the market requires constant attention. Turn your head, and in the blink of an eye prospective investments have already shot up on the back of good news such as mergers or encouraging clinical data readouts. The last day has seen several names go moon bound following recent positive developments. Let’s take a look at who the investing gods are smiling upon today.E*Trade Financial Corp. (ETFC)Shares of E*Trade have shot up by over 25% following the announcement that Morgan Stanley has acquired the online broker for $13 billion. The investment firm will pay $58.74 a share, while the merger will provide the newly formed company with $3.1 trillion in client assets. The deal is expected to be finalized in the fourth quarter.The purchase comes hot on the heels of last year’s merger of Charles Schwab and TD Ameritrade. Since then, speculation was rife that E*Trade could be the next in line to be bought out. E*Trade brings in deposits of roughly $56 billion a year, making the company an appealing target for Morgan Stanley as it looks to make headway in consumer finance. The word on the Street rings largely bullish on this online trading firm, with TipRanks analytics demonstrating ETFC as a Buy. Out of 10 analysts tracked in the last 3 months, 6 are bullish on E*Trade stock, 3 remain sidelined, and 1 is bearish. However, with an average price target of $50.40, ETFC has an implied 12% downside from current levels. (See E*Trade's stock analysis at TipRanks)Adesto Technologies Corp (IOTS)Shares of semiconductor company Adesto Technologies have surged by 55% on the back of news that Anglo-German chip designer Dialog Semiconductor has put $500 million on the table to buy the California-based company. Adesto’s field of expertise is Internet of Things (IoT) technology, for which it provides application-specific semiconductors and embedded systems.Dialog makes power-management chips and low-energy Bluetooth products which are used in fitness trackers and cordless earphones. The acquisition was agreed at a price of $12.55 per share which amounts to $500 million.It has been relatively quiet when it comes to analyst activity. In the last three months, only 3 analysts have issued ratings. With 2 "hold" ratings and 1 "buy," the word on the Street is that IOTS is a Moderate Buy. Based on the $12.68 average price target, shares seem to be fully valued at current levels. (See Adesto stock analysis at TipRanks)Brickell Biotech (BBI)Naturally, though, leaving both in the dust is a biotech stock. Brickell Biotech has a market cap of just $32.6 million, but if it keeps up today’s performance it won’t be a micro-cap for much longer. BBI stock is up by over 113% on the back of positive trial data.The skin disease focused clinical stage company announced positive results from its Phase 2b study with sofpironium bromide in patients with primary axillary hyperhidrosis (excessive sweating, especially in the armpit). sofpironium bromide is a new molecular entity and “soft” drug that belongs to a class of medications called anticholinergics. The study showed the significant sustained reductions in sweating severity and was well tolerated.Today’s surge continues an excellent week for the micro-cap. Brickell stock soared by over 42% on Tuesday following the resolution of a license dispute. The point of contention related to the license agreement for sofpirononium bromide between Brickell, and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively “Bodor”). Under the terms of the settlement Brickell has agreed to pay $1.0M upfront, up to $2.5M in milestones ($1.0M in cash and $1.5M in stock). Additionally, the company will pay a low single-digit royalty related to a newly filed patent application.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • GlobeNewswire

    Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive results from its Phase 2b study with sofpironium bromide in patients with primary axillary hyperhidrosis were published in the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The paper, entitled “Efficacy and Safety of Topical Sofpironium Bromide Gel for the Treatment of Axillary Hyperhidrosis: A Phase 2, Randomized, Controlled, Double-Blinded Trial,” is now available online (Journal Pre-proof) at (https://doi.org/10.1016/j.jaad.2020.02.016) and will be published in a future print edition of JAAD.

  • GlobeNewswire

    Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

    Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced Brickell, and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively, “Bodor”), entered into a settlement agreement and an amended license agreement. This resolves the previously disclosed dispute related to the sofpironium bromide license agreement and allows the Company to continue its efforts to develop sofpironium bromide for the treatment of hyperhidrosis, a life-altering medical condition with an estimated 15 million sufferers in the United States.

  • GlobeNewswire

    Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its development partner, Kaken Pharmaceutical Co. Ltd. (“Kaken”) submitted a new drug application for approval of manufacturing and marketing for sofpironium bromide in Japan for primary axillary hyperhidrosis. The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.

  • GlobeNewswire

    Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., Nov. 13, 2019 -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated.

  • GlobeNewswire

    Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

    Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI), a clinical-stage pharmaceutical company, today announced that it has initiated an arbitration proceeding pursuant to Article 9 of the License Agreement previously entered into between Bodor Laboratories, Inc. (“Bodor”), Nicholas S. Bodor and Brickell with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor for tortious interference with Brickell’s business relations.

  • GlobeNewswire

    Brickell Biotech Completes Merger with Vical

    Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, today announced the completion of its merger with Vical Incorporated (“Vical”), following approval by Vical’s stockholders.